Next Article in Journal
Cross-Dataset Evaluation of Deep Learning Networks for Uterine Cervix Segmentation
Next Article in Special Issue
Mucinous Cancer of the Ovary: Overview and Current Status
Previous Article in Journal
Development of a Flow-Free Automated Colorimetric Detection Assay Integrated with Smartphone for Zika NS1
Previous Article in Special Issue
Sarcopenic Factors May Have No Impact on Outcomes in Ovarian Cancer Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 10
Issue 1
10.3390/diagnostics10010043
Review Report
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Diagnostics 2020, 10(1), 43; https://doi.org/10.3390/diagnostics10010043
by McKayla J. Riggs 1, Prakash K. Pandalai 2, Joseph Kim 2 and Charles S. Dietrich 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Diagnostics 2020, 10(1), 43; https://doi.org/10.3390/diagnostics10010043
Submission received: 19 December 2019 / Revised: 9 January 2020 / Accepted: 10 January 2020 / Published: 14 January 2020
(This article belongs to the Special Issue Ovarian Cancer: Characteristics, Screening, Diagnosis and Treatment)

Round 1

Reviewer 1 Report

Dear authors

The paper describes the use oh HIPEC in primary and recurrent ovarian cancers. Both surgical and oncological point of views were well described. The paper is clearly written and of interest for surgeons, medical oncologist and translational scientists.

There are a few minor points to be addressed:

Literature appears old with a few cited papers in the last two years.

Conclusions should be expanded with a point of view from authors on what could be the best strategies to follow for improving the use of HIPEC in clinic.

Author Response

We appreciate the recommendations provided by the first reviewer. He or she acknowledged that our review includes literature that seems dated. Currently, HIPEC use in ovarian cancer is not yet standard of care. Recent literature on this topic is scant, and one of our goals with this review article is to highlight areas for future exploration. Hopefully, our article may spark further interest into new investigation into this topic.

We expanded the conclusion to further clarify the points of interest/debate to make HIPEC in ovarian cancer more standardized and clinically applicable.

Author Response File: Author Response.docx

Reviewer 2 Report

This review emphasises on the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. It nicely highlights the brief history of HIPEC and its use in primary as well as recurrent cancer. 

Author Response

We appreciate the review and positive feedback by this reviewer. Grammatical changes were made as indicated in the edited manuscript.

Author Response File: Author Response.docx

Reviewer 3 Report

This is an overview on the introduction, evolution and effectiveness of HIPEC along with CRS in the treatment of primary and recurrent ovarian cancer. 


Although comprehensive, the manuscript should be more succinct and focused and the issues related to the use of HIPEC in ovarian cancer should be more clearly presented in the last paragraph of conclusions.

Please pay also attention to some minor spelling mistakes (see lines 114,181, 182).

Author Response

We appreciate the recommendations by this reviewer. We shortened the manuscript to better clarify our points, particularly in the conclusion, but also eliminated portions to make it more succinct.  The lines were numbered but spelling errors did not correspond as described by the reviewer. Made grammatical and spelling changes as needed throughout the document.

Author Response File: Author Response.docx

Back to TopTop